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During recent decades, substantial progress has been made in clinical strategies for treating hematological malignancies. Not 
only did China benefit from the global progression in the management of acute promyelocytic leukemia, 
risk-stratification-directed strategies for acute or chronic leukemia and haploidentical hematopoietic stem cell transplantation, 
the unique system developed by Chinese doctors has also become inspiration for refining global clinical practice. The multi- 
center trials and collaborations adhering to international standards might further strengthen the global impact and lead the way 
in specific fields of research worldwide. 
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Hematological malignancies, including acute and chronic 
leukemia, lymphoma and multiple myeloma, constitute a 
series of critical life-threatening diseases, especially in chil-
dren and adolescents [1]. During recent decades, substantial 
progress has been made in clinical strategies for treating 
hematological malignancies, which have shifted from “in-
curable” to “curable”. In general, the 3- to 6-year dis-
ease-free survival (DFS) of hematological malignancies in 
comprehensive hematology centers in China reached 
60%–70%, and in several diseases the 2-year DFS exceeded 
95% [2–8]. In this process, Chinese patients benefited from 
the global developments of hematological malignancy ther-
apy, not only with respect to therapeutic strategies but also 
with regard to the methodology in clinical trial design, 
standardization of clinical practice and multi-center cooper-
ation. The innovations of Chinese doctors also prompted 
global progression, especially in managing acute promye-
locytic leukemia (APL), risk-stratification-directed strate-
gies for leukemia and haploidentical hematopoietic stem 
cell transplantation (Haplo-HSCT). The present review fo-
cuses on the unique anti-malignancy clinical strategies in-
novated by Chinese doctors and provides insight into their 
global impact.   
1  Acute promyelocytic leukemia (APL) 
In the “chemotherapy era” with daunorubicin or earlier, 
APL was once a highly fatal malignancy because of a high 
incidence (approximately 30%) of early death caused by 
hemorrhage and so on, while the first complete remission 
rate (CR1) was less than 50% [9–11]. Chinese doctors had 
made special contributions by introducing targeted therapy 
including all-trans retinoic acid (ATRA) and arsenic acid  
1184 Lv M, et al.   Sci China Life Sci   December (2015) Vol.58 No.12 
for APL [12]. In the late 1980s, the Shanghai group [13,14] 
first introduced ATRA into the clinics, and the CR1 rate 
reached 90% without increasing the risk of hemorrhage. 
These findings of ATRA were soon replicated in France and 
the USA, which advocated the application of ATRA in both 
induction and maintenance compared with the standard 
chemotherapy using daunorubicin and cytarabine [15,16]. 
Because the therapeutic effects of ATRA were limited due 
to the high relapse rate in maintenance [17], the introduction 
of arsenic acid from traditional Chinese medicine (in the 
form of arsenic trioxide or arsenic disulfide) by Harbin, 
Shanghai and Beijing further improved the clinical out-
comes of APL, yielding the 3- to 6-year DFS of about 
80%–90% [18–20]. Although arsenic trioxide (ATO) was 
discovered more than a decade before the discovery to 
ATRA, this unique system was underestimated or ignored 
outside of China until a series of clinical reports and mecha-
nism studies were conducted at the molecular level according 
to international standards [21–24]. Subsequently, ATRA 
plus ATO were gradually accepted as the first-line treatment 
over chemotherapy in the management of APL [25–28].  
Therefore, modern biomedical approaches and well-  
designed clinical trials play key roles in connecting the 
unique systems of China with those of the world. Real-
gar-Indigo naturalis formula (RIF) for APL is another con-
crete example. The formula is representative of traditional 
Chinese medicine, prescribing a combination of plant spe-
cies and minerals based on clinical experience. Although 
the clinical efficacy of RIF has been proven in a single-arm 
clinical trial in the 1990s [29], the international hematology 
community did not recognize the benefits of RIF because of 
the obscure mechanisms and the absence of strict trials. By 
dissecting the mode of action of RIF at the molecular, cel-
lular, and organism levels, the Shanghai group [30] reported 
tetra-arsenic tetrasulfide as a principal component of RIF, 
whereas other adjuvant ingredients yielded synergy in tar-
geting APL cells in vitro and in vivo. Recently, a prospec-
tive, multi-center, randomized, controlled study led by the 
Shanghai and Beijing groups proved that oral RIF achieved 
a high rate of remission and survival comparable with that 
of intravenous ATO as a front-line treatment for newly di-
agnosed APL, the 3-year overall survival rate (OS) was 
99.1% (RIF) and 96.6% (ATO) (Table 1) [5]. Later, in a 
single-arm study of non-high-risk patients by the Beijing 
group [31,32], oral RIF and ATRA were administered to 
patients in a largely home-based treatment protocol, pro-
moting the new era to “Cure leukemia in out-patient de-
partment”.  
Despite the high incidence of CR and OS, resistance to 
arsenic acid resulted in a worse outcome. Amino acid sub-
stitutions of A216V and L218P in the promyelocytic leu-
kemia protein (PML) B2 domain have been detected in pa-
tients clinically resistant to arsenic trioxide [33], recently 
the Beijing group identified 4 new mutations in PML tran-
scripts with A216T, S214L, L217F, and S220G, which 
suggested the presence of a PML mutational hot-spot do-
main (C212-S220). These mutations may be helpful in 
guiding risk-stratification-directed treatment choices in the 
 
Table 1  Recent multi-center studies on hematologic malignancies in Chinaa) 





Main Results Conclusions Publication 
AML 
CR1 
HID vs. ISD 
allo-HSCT 
Donor 
availability 3 450 
3-year DFS:HID (74%) and ISD 
(78%) (P=0.34) 
3-year OS: HID (79%) and ISD 
(82%) (P=0.36) 
HID achieves similar out-
comes to ISD HSCT for AML 
CR1 
Wang et al. [3] 
AML 
HAA vs. HAD 
vs. DA 
RCT 17 620 
CR: HAA (71%) vs. HAD (67%) vs. 
DA (61%) 
3-year EFS: 
HAA (35.4%) vs. HAD (32.7%) vs. 
DA (23.1%) 
HAA is a treatment option for 
young, newly diagnosed pa-
tients with AML 









HSCT (22.1%) vs. Chemo (78.9%)
5-year DFS (61.7%) vs. Chemo 
(19.6%) 
MRD-directed pre-transplant 
risk stratification may im-
prove the outcome of t(8;21) 
AML in CR1 







Multivariate: MMR in first 3 months
CIR: HR 0.07 (0.02–0.26) 
(P=0.001) 
LFS: HR 0.13 (0.05–0.34) 
(P=0.001). 
MRD within 3 months after 
HSCT was independent factor 
for CIR and LFS, not c-KIT 
mutations 





RCT 13 267 
MMR 12m: Nilotinib (52.2)% vs. 
Imatinib (27.8%) (P<0.0001) 
MMR at 12 months were 
superior with nilotinib vs 
imatinib in CML-CP 
Wang et al. [58] 
a) APL, acute promyelocytic leukemia; RIF, Realgar-Indigo naturalis formula; ATRA, all-trans retinoic acid; RCT, randomized controlled trial; OS, 
overall survival rate; DFSAML, acute myeloid leukemia; HAA, homoharringtonine, cytarabine, aclarubicin; HAD, homoharringtonine, cytarabine, dauno-
rubicin; DA, cytarabine, daunorubicin; EFS, event free survival; CIR, cumulative incidence of relapse; MRD, minimal residual disease; MMR, major molec-
ular response; CML-CP, chronic myeloid leukemia in chronic phase; HID, haploidentical donor; ISD, HLA-identical sibling donor. 
 Lv M, et al.   Sci China Life Sci   December (2015) Vol.58 No.12 1185 
relapse APL and finding new strategies for overcoming ar-
senic acid resistance [34]. Because ATO can hardly pene-
trate the blood-brain-barrier, the management of extra me-
dullary relapse of APL in the central nervous system (CNS) 
was difficult. The Harbin group [35] first demonstrated that 
neuron cells were more tolerant to ATO than leukemia cells 
in vitro, based on these findings, the co-infusion of ATO 
and mannitol was introduced to patients with CNS relapse, 
as comparable arsenic levels were achieved in the cerebro-
spinal fluid and plasma, these patients exhibited improved 
outcomes, with a 5-year OS at 82.4% [36]. 
By incorporating modern molecular biotechnology into 
the discoveries of traditional Chinese medicine, fitting this 
unique system the international standards, Chinese doctors 
globally introduced a new era of therapeutic strategy for 
managing APL.  
2  Acute myeloid leukemia (AML) and acute 
lymphoblastic leukemia (ALL) 
To manage AML and ALL, Chinese doctors made the fol-
lowing innovative contributions: the identification of genet-
ic abnormalities; novel regimens for chemotherapy or tar-
geted therapy; and development of risk-stratification-   
directed therapy.  
The Shanghai group [37] and several other centers in 
China pioneered the genetic analysis of acute leukemia 
worldwide. Using exome sequencing, the mutations of 
DNA-methyltransferase 3A (DNMT3A) in acute monocytic 
leukemia were found to be correlated with the alterations of 
DNA methylation patterns and gene expression profiles. In 
cohorts of thousands of patients with newly diagnosed ALL, 
it was revealed that Chinese ALL patients demonstrated 
more adverse prognostic factors, such as breakpoint cluster 
region-Abelson (BCR-ABL), than western patients [38,39]. 
In AML, DNMT3A and mixed-lineage leukemia (MLL) 
mutations were associated with OS and DFS, whereas bial-
lelic CCAAT/enhancer-binding protein alpha (CEBPA) or 
nucleophosmin1 (NPM1) mutations without DNMT3A mu-
tations exhibited a better OS. Recently, using whole-   
genome sequencing, the Tianjin group [40,41] suggested 
that point mutations in SET domain containing 2 (SETD2) 
were associated with multiple major chromosomal aberra-
tions, such as H3K36 trimethylation, and promoted the 
self-renewal potential of leukemia stem cells. In addition to 
genetic mutations, the series of aberrantly expressed mi-
croRNA and distinct metabolism signatures were indicated 
as prognostic markers for acute leukemia [42–44]. Not only 
did these cytogenetic and molecular abnormalities provide 
prognostic value, they also yielded insight into the mecha-
nisms of leukemogenesis and contributed to the potential 
endeavors to find new therapeutic strategies.   
Homoharringtonine, derived from a natural plant alka-
loid, has been widely used in China to treat patients with 
AML; however, its global impact has been limited as in the 
case of ATO. Recently, a multi-center, randomized, con-
trolled trial in a large population from 17 institutions in 
China helped to solve this problem. Three induction regi-
mens were assigned at a 1:1:1 ratio, which included HAA 
(homoharringtonine, cytarabine, aclarubicin), HAD (homo-
harringtonine, cytarabine, daunorubicin) and DA (cytara-
bine, daunorubicin). HAA was superior to DA, which was 
still the first-line treatment of induction therapy, with a su-
perior CR rate of induction (73% vs. 61%, P=0.0108) and 
3-year DFS (35.4% vs. 23.1%, P=0.0023) [45]. As a sem-
isynthetic version of homoharringtonine, omacetaxinemepe 
succinate was recently approved by the Food and Drug 
Administration for the treatment of advanced leukemia; this 
unique agent with Chinese characters might play an in-
creasing role in AML therapy and yield more influence on 
the guidelines dominated in the western world. Many can-
didate agents, such as oridonin, a diterpenoid extracted from 
medicinal herbs, targeting AML1-eight-twenty one onco-
protein (ETO) fusion protein and inhibiting the activity of 
c-Kit(+) leukemia-initiating cells in t(8;21) AML, might be 
a potential lead compound for the molecular target-based 
therapy of leukemia [46,47]. 
Although acute myeloid leukemia (AML) with t(8;21) 
generally has a favorable prognosis, relapse occurs in 
40%–60% of the patients, and the long-term survival is un-
satisfactory [48]. Therefore, the early identification of pa-
tients with high-risk relapse in chemotherapy might provide 
valuable information regarding the selection of more ag-
gressive strategies, such as allogeneic hematopoietic stem 
cell transplantation (allo-HSCT) as post remission therapy. 
It has been demonstrated in a multicenter trial in China that 
the minimal residual disease (MRD) status after the second 
consolidation, rather than induction or first consolidation, 
could discriminate high-risk relapse patients. Allo-HSCT 
could reduce the incidence of relapse and improve the sur-
vival rate compared with chemotherapy for these high-risk 
patients (cumulative incidence of relapse/CIR, HSCT vs. 
chemotherapy: 22.1% vs. 78.9%, P<0.0001). Therefore, 
MRD-directed pre-transplant risk stratification may im-
prove the outcome of t(8;21) AML in CR1 [49]. Further-
more, for those high-risk patients who received allo-HSCT, 
MRD within 3 months after HSCT, rather than c-KIT muta-
tions, was suggested as an independent factor for CIR and 
DFS in another multi-center study [50].  
In sum, three aspects of the contributions by Chinese 
doctors could be integrated as “Prognostic genetic bi-
omarkers—Regimens solutions—Risk-stratification-direc- 
ted strategies,” which are in accordance with the trends of 
“Precision Medicine” [51]. 
3  Chronic myeloid leukemia (CML) 
Chinese patients with CML benefited from the introduction 
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of tyrosine kinase inhibitors (TKIs) [52,53]. Because the 
innovations of new TKIs were monopolized by pharmaceu-
tical industries in the western world, it is worth considering 
how to present “the voice from China” in this situation. 
Allo-HSCT is no longer considered to be the first-line 
therapy for managing CML in the “TKI era” in developed 
countries. There is a shortage of evidence-based studies to 
address the optimization of therapeutic strategy for CML 
other than TKI. In prospective studies of China, imatinib 
results in comparable or better outcomes than an human 
leukocyte antigen (HLA)-identical sibling allo-HSCT as an 
initial therapy for CML-CP (chronic phase) [6], whereas 
allo-HSCT confers significant survival advantages for high- 
and intermediate-risk patients with CML in AP (accelerated 
phase) or BC (blast crisis) compared with imatinib [7,54]. 
These studies helped to refine the European Leukemia Net 
guidelines for CML [55]. 
As BCR-ABL transcripts level play a critical role in 
guiding therapeutic strategies, it would be impossible to 
directly compare these results between different laboratories 
in the absence of uniform standards, not to mention initiat-
ing a multi-center study. Rather than using the log reduction 
method, the molecular response evaluated by BCR-ABL 
(IS) can better differentiate patients and allows for a com-
parison among molecular response results from different 
laboratories [56]. Through international cooperation, Peking 
University’s laboratory was first certified by the BCR-ABL 
(IS) international laboratory and led the standardization of 
BCR-ABL monitoring in 23 central laboratories throughout 
China [57]. Based on uniform molecular monitoring, the 
“CML Consortium of China” was established and multi- 
center studies achieved promising results [58]. 
4  Haploidentical hematopoietic stem cell trans-
plantation (Haplo-HSCT) 
Allo-HSCT provides the powerful curative weapons for 
patients with the majority of hematological malignancies. 
Due to the “One Child Policy,” there has been a shortage of 
HLA-identical siblings for Chinese patients who need 
HSCT, whereas only 11% could find matched unrelated 
donors in the total patients who tried to search for donors in 
“China Marrow Donor Program.” Therefore, haplo-HSCT 
based on related family donors has a unique role in the 
treatment of hematologic diseases in China. Nevertheless, 
haplo-HSCT was once a dream because of the high inci-
dence of rejection and severe graft-versus-host disease 
(GvHD) [59]. 
Based on series of mechanism research on cytokines in-
duced immune tolerance [60–63], Peking University research-
ers developed a novel approach for HLA-mismatched/ 
haploidentical myeloablative blood and marrow transplanta-
tion without in vitro T cell depletion within the last 10 years 
(Beijing Protocol)[8,64]. Combinations of granulocyte col-
ony-stimulating factor (G-CSF) and anti-thymocyte globu-
lin (ATG) have been confirmed to play a key role in over-
coming HLA barriers [65,66], probably by immune regula-
tory cells, such as Th17/Tc 17, Treg, and myeloid-derived 
suppressor cells (MDSCs) [67–70]. In a prospective,  
randomized trial, it was suggested that 10 mg kg1 ATG was 
superior to 6 mg kg1 for lower grades III–IV acute  
GvHD [71]. 
In several single-center studies, haplo-HSCT was found 
to have similar therapeutic effects compared to HSCT with 
HLA identical sibling donor (ISD) [72] or matched unrelat-
ed donor (URD) [73], and may improve the outcomes of 
children compared with umbilical cord blood (UCB) trans-
plantation [74]. Recently, in multi-center studies, hap-
lo-HSCT exhibited a similar outcome as ISDs HSCT on 
adults with intermediate- or high-risk acute myeloid leuke-
mia in CR1 [3]. Additionally, haplo-HSCT can achieve a 
desirable health-related quality of life (HRQoL) and a lower 
risk of late effects compared with ISD HSCT [75,76]. 
Haplo-HSCT is superior to chemotherapy as post-   
remission treatment for intermediate- or high-risk AML or 
ALL in CR1. In a recent prospective study with intermedi-
ate- or high-risk AML, it was revealed that haplo-HSCT 
resulted in a lower cumulative incident of relapse (12.0% 
vs. 57.8%; P<0.0001) and superior 4-year DFS (73.1% vs. 
44.2%; P<0.0001) compared with the chemotherapy-alone 
group [77]. Similar results were observed among high- and 
stand-risk Ph-negative ALL CR1 patients after haplo- 
HSCT[4] [78].  
As the new era in which “everyone has a donor” arri-  
ves [79], there will be a shift from donor shortage to diver-
sification. HLA plays a predominant role in selection of the 
best donor in unrelated transplants, nevertheless, it has not 
been significantly correlated with transplant outcomes in 
haplo-HSCT [80,81]; therefore, we might focus on factors 
other than HLA to determine the impact on transplant out-
comes. Based on a large sample size and relative consisten-
cy of transplant variables, the Beijing group [82] proposed 
an algorithm other than HLA for donor selection. It was 
suggested that choosing young, male, non-inherited mater-
nal antigens(NIMA)-mismatched donors is reasonable. The 
transplants from older mothers and non-inherited paternal 
antigens (NIPA)-mismatched donors should probably be 
avoided. Additionally, donor-specific anti-HLA antibodies 
(DSAs) were indicated to be associated with primary graft 
failure (GF), transplant-related mortality and inferior overall 
survival following haplo-HSCT [83]. Donor selection based 
on other non-HLA systems, such as donor inhibitory killer 
cell immunoglobulin-like receptors (KIRs), remain to be 
further elucidated [84].  
Since “Beijing Protocol” has been widely incorporated 
into clinical practice in most comprehensive HSCT centers 
of China, haplo-HSCT has become the largest donor source 
compared with ISD donors and take nearly 48% of total 
allo-HSCT cases in China (Figure 1). “Beijing Protocol”  
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Figure 1 (color online)  ISD vs. Haplo-HSCT in China (2008–2014). 
According to data collected by the Chinese HSCT registry group from 60 
active centers of China between 2008 to 2014. Haploidentical donor be-
come the largest donor source in China compared with ISD since 2013. 
The Y-axis represents the percentage of hematopoietic stem cell transplan-
tation (HSCT) from human leukocyte antigen-identical sibling donor (ISD) 
or haploidentical donor (Haplo) in total allogeneic HSCT cases, the X-axis 
represents years.  
was also replicated and conducted with promising results by 
Di Bartolomeo et al. [85] in Europe. As Handgretinger 
commented, “more than half of the HLA haplotype mis-
matched transplantations performed worldwide will follow 
similar protocols (Beijing Protocol) [86]. 
The development of Haplo-HSCT in China has changed 
the current situation of the international HSCT system. 
More innovative and standard clinical systems like “Beijing 
Protocol” are needed to keep the global impact of China.  
5  Conclusions and prospective 
As one of the most dynamic fields in translational medicine 
and precision medicine, there are both opportunities and 
challenges to anti-hematological malignancies. Only could 
deep mechanism studies, well designed clinical trials and 
multicenter collaborations bring the unique system of China 
to the world, which might be adopted into international sys-
tems or standards, and contribute to the global progression 
in fighting against hematologic malignancy. 
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